JPMorgan Chase CEO reduces $150 million in stock holdings
六月清晨搅
发表于 2024-2-24 14:03:27
226
0
0
BEIJING, February 24th (Xinhua Finance) -- According to a document released by the US Securities and Exchange Commission on February 22nd, Jamie Damon, CEO of JPMorgan Chase Bank, has reduced his holdings of approximately $150 million in the bank's stock.
Reuters reported that this is the first time Damon has reduced his holdings in the bank's stock since becoming CEO of JPMorgan Chase in 2005.
On June 19, 2012, in Washington, D.C., the President and CEO of JPMorgan Chase Bank, Jamie Damon, answered questions from lawmakers during a hearing of the House Finance Committee. Photo by Xinhua News Agency reporter Fang Zhe
JPMorgan Chase wrote in a document last October that Damon and his family hold 8.6 million shares of JPMorgan Chase and intend to sell 1 million of them.
So far, Damon has sold approximately 822000 shares.
A spokesperson for JPMorgan Chase said in October last year that Dimon's reduction in stock holdings is not related to leadership changes, and there are currently no plans to sell more, but it is not ruled out that he will reduce his holdings again in the future.
Damon's annual salary increased by 4.3% to $36 million in 2023, making him the longest serving CEO among major US banks. JPMorgan Chase Bank was the most profitable US bank last year and also the largest bank in terms of asset size in the United States.
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- Morgan Stanley: Increases Broadcom's target price to $233
- Goldman Sachs: Increases Costco target price to $1052
- Morgan Stanley raises IBM target price to $222
- JPMorgan Chase: Upgrades CBRE rating to $163 increase target price
- Pfizer expects revenue of $61 billion to $64 billion in 2025, with an estimated $63.23 billion
- JPMorgan Chase: Increases CrowdStrike Target Price from $372 to $418
- Morgan Stanley: Lowering Western Oil Target Price to $63
- Goldman Sachs: Increases Boston Scientific's target price to $103
- Goldman Sachs: Raise Fox's target price to $57
